Skip to results

Area of interest

Area of interest

Type (1 selected)

Type

Guidance programme

Showing 301 to 312 of 312

Guidance and quality standards awaiting development
TitleType
Vorasidenib for treating astrocytoma or oligodendroglioma with IDH1 or IDH2 mutations after surgery in people 12 years and over TS ID 11974Technology appraisal guidance
Vosoritide for treating achondroplasia in children TSID 12001Technology appraisal guidance
Vosoritide for treating achondroplasia in children and young people under 18 years [ID3807]Technology appraisal guidance
WP1048 for treating grass pollen allergy in people aged 18 to 60 TS ID 10467Technology appraisal guidance
Xeomin (botulinum neurotoxin type A) for treating lower limb spasticity TS ID 11902Technology appraisal guidance
Xevinapant with platinum-based chemotherapy and radiotherapy for untreated locally advanced squamous cell head and neck cancer [ID6199]Technology appraisal guidance
Zamtocabtagene autoleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more therapies TS ID 10765Technology appraisal guidance
Zamtocabtagene autoleucel for treating relapsed or refractory diffuse large B-cell lymphoma when high-dose chemotherapy and autologous stem cell transplant are unsuitable TS ID 10477Technology appraisal guidance
Zanidatamab for treating HER2-positive advanced biliary tract cancer after 1 or more systemic treatments TS ID 11952Technology appraisal guidance
Zavegepant for treating acute migraine TSID 11998Technology appraisal guidance
Zolbetuximab with nab-paclitaxel and gemcitabine for untreated claudin 18.2-positive metastatic pancreatic cancer [ID6444]Technology appraisal guidance
Zuranolone for treating severe postnatal depression ID6431Technology appraisal guidance

Results per page

  1. 10
  2. 25
  3. 50
  4. All